Retinal nerve fiber layer thickness in patients receiving chronic antivascular endothelial growth factor therapy

American Journal of Ophthalmology

Volumn 150, Issue 4, 2010, Pages

  Horsley, Michael B ^a   Mandava, Naresh ^a   Maycotte, Marco A ^a   Kahook, Malik Y ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; APTAMER; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MALE; MONOTHERAPY; NERVE FIBER; OBSERVATIONAL STUDY; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETINA NERVE CELL; RETROSPECTIVE STUDY; THICKNESS; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; INJECTION; OPTIC DISK; PATHOLOGY; RETINA GANGLION CELL; RETREATMENT; VITREOUS BODY; WET MACULAR DEGENERATION;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; APTAMERS, NUCLEOTIDE; BEVACIZUMAB; FEMALE; HUMANS; INJECTIONS; MALE; NERVE FIBERS; OPTIC DISK; RANIBIZUMAB; RETINAL GANGLION CELLS; RETREATMENT; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY; WET MACULAR DEGENERATION;

EID: 77957258399     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2010.04.029     Document Type: Article

References (21)

1. M. Funk, D. Karl, and M. Georgopoulos Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab Ophthalmology 116 12 2009 2393 2399
2. R.O. Schlingemann, and A.N. Witmer Treatment of retinal diseases with VEGF antagonists ProgBrain Res 175 2009 253 267
3. M.E. Iliev, D. Domig, and U. Wolf-Schnurrbursch Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma Am J Ophthalmol 142 6 2006 1054 1056
4. M. Sondell, G. Lundborg, and M. Kanje Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and schwann cell proliferation in the peripheral nervous system J Neurosci 19 14 1999 5731 5740 (Pubitemid 29327910)
5. M.Y. Kahook, A.E. Kimura, L.J. Wong, D.A. Ammar, M.A. Maycotte, and N. Mandava Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections Ophthalmic Surg Lasers Imaging 40 3 2009 293 295
6. S.J. Bakri, J.S. Pulido, C.A. McCannel, D.O. Hodge, N. Diehl, and J. Hillemeier Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab Eye 23 1 2009 181 185
7. I.A. Falkenstein, L. Cheng, and W.R. Freeman Changes of intraocular pressure after intravitreal injection of bevacizumab (Avastin) Retina 27 8 2007 1044 1047 (Pubitemid 350304005)
8. R.E. Frenkel, L. Mani, and A.R. Toler Intraocular pressure effects of pegaptanib (Macugen) injection in patients with and without glaucoma Am J Ophthalmol 143 6 2007 1034 1035 (Pubitemid 46764645)
9. J.E. Kim, A.V. Mantravadi, E.Y. Hur, and D.J. Covert Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents Am J Ophthalmol 146 6 2008 930 934
10. H. Hollands, J. Wong, R. Bruen, R.J. Campbell, S. Sharma, and J. Gale Short-term intraocular pressure changes after intravitreal injection of bevacizumab Can J Ophthalmol 42 6 2007 807 811
11. K. Nouri-Mahdavi, D. Hoffman, A.L. Coleman Advanced Glaucoma Intervention Study Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study Ophthalmology 111 9 2004 1627 1635 (Pubitemid 39179673)
12. S.J. Bakri, C.A. McCannel, A.O. Edwards, and D.M. Moshfeghi Persistent ocular hypertension following intravitreal ranibizumab Graefes Arch Clin Exp Ophthalmol 246 7 2008 955 958
13. A. Jalil, C. Fenerty, and S. Charles Intravitreal bevacizumab (Avastin) causing acute glaucoma: an unreported complication Eye 21 12 2007 1541
14. Y. Wang, D. Fei, M. Vanderlaan, and A. Song Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro Angiogenesis 7 4 2004 335 345 (Pubitemid 40767935)
15. R.K. Seth, S. Salim, M.B. Shields, and R.A. Adelman Assessment of optic nerve cup-to-disk ratio changes in patients receiving multiple intravitreal injections of antivascular endothelial growth factor agents Retina 29 7 2009 956 959
16. I. Zachary Neuroprotective role of vascular endothelial growth factor: signaling mechanisms, biologic function, and therapeutic potential Neurosignals 14 5 2005 207 221 (Pubitemid 41661355)
17. E. Storkebaum, D. Lambrechts, and P. Carmeliet VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection Bioessays 26 9 2004 943 954 (Pubitemid 39273068)
18. K. Nishijima, Y.S. Ng, and L. Zhong Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury Am J Pathol 171 1 2007 53 67 (Pubitemid 47339226)
19. F.A. Medeiros, L.M. Zangwill, and L.M. Alencar Detection of glaucoma progression with stratus OCT retinal nerve fiber layer, optic nerve head, and macular thickness measurements Invest Ophthalmol Vis Sci 50 12 2009 5741 5748
20. D.L. Budenz, M.J. Fredette, W.J. Feuer, and D.R. Anderson Reproducibility of peripapillary retinal nerve fiber thickness measurements with stratus OCT in glaucomatous eyes Ophthalmology 115 4 2008 661 666
21. L.A. Paunescu, J.S. Schuman, and L.L. Price Reproducibility of nerve fiber thickness, macular thickness, and optic nerve head measurements using StratusOCT Invest Ophthalmol Vis Sci 45 6 2004 1716 1724 (Pubitemid 38868963)